Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AVROBIO, Inc.

< Previous 1 2 Next >
AVROBIO and Tectonic Therapeutic Announce Merger
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Explore Strategic Alternatives
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Leadership Transition
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Share Comprehensive Gaucher Disease Program Update
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Participate in Four Upcoming Investor Conferences in September
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO to Participate in Two Upcoming Investor Conferences in August
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
From AVROBIO, Inc.
Via Business Wire
Tickers AVRO
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.